|
|
Blood, 15 October 2006, Vol. 108, No. 8, pp. 2608-2615.
Prepublished online as a Blood First Edition Paper on June 29, 2006; DOI 10.1182/blood-2005-12-019919.
Previous Article | Table of Contents | Next Article 
HEMOSTASIS, THROMBOSIS, AND VASCULAR BIOLOGY
Soluble HLA-G1 inhibits angiogenesis through an apoptotic pathway and by direct binding to CD160 receptor expressed by endothelial cells
Pierre Fons,
Sophie Chabot,
Judith E. Cartwright,
Francoise Lenfant,
Fatima L'Faqihi,
Jerome Giustiniani,
Jean-Pascal Herault,
Genevieve Gueguen,
Françoise Bono,
Pierre Savi,
Maryse Aguerre-Girr,
Sylvie Fournel,
François Malecaze,
Armand Bensussan,
Jean Plouët, and
Philippe Le Bouteiller
From the Institut de Pharmacologie et Biologie Structurale, Centre National de la Recherche Scientifique Unité Mixte de Recherche 5089, Toulouse, France; Sanofi-Aventis Research, Toulouse, France; Institut National de la Santé et de la Recherche Médicale Unité 563/Université Paul Sabatier, Hôpital Purpan, Toulouse, France; Department of Basic Medical Sciences, St. George's, University of London, United Kingdom; Institut National de la Santé et de la Recherche Médicale Unité 659, Faculté de Médecine de Créteil, Créteil, France; and Institut National de la Santé et de la Recherche Médicale Unité 689, Institute des Vaisseaux et du Sang, Paris, France.
HLA-G is a major histocompatibility complex class Ib molecule whose constitutive tissue distribution is restricted mainly to trophoblast cells at the maternal-fetal interface during pregnancy. In this study, we demonstrated the ability of the soluble HLA-G1 (sHLA-G1) isoform to inhibit fibroblast growth factor-2 (FGF2)-induced capillary-like tubule formation. Using a rabbit corneal neovascularization model, we further showed that sHLA-G1 inhibits FGF2-induced angiogenesis in vivo. We also demonstrated that sHLA-G1 induces endothelial cell apoptosis through binding to BY55/CD160, a glycosylphosphatidylinositolanchored receptor expressed by endothelial cells. Furthermore, we showed that the specific CL1-R2 anti-CD160 monoclonal antibody mimics sHLA-G1-mediated inhibition of endothelial cell tube formation and induction of apoptosis. Thus, the engagement of CD160 in endothelial cells may be essential for the inhibition of angiogenesis. sHLA-G1/CD160-mediated antiangiogenic property may participate in the vascular remodeling of maternal spiral arteries during pregnancy, and, given that we found that CD160 is strongly expressed in the vasculature of a murine tumor, it offers an attractive therapeutic target for preventing pathologic neovascularization.

CiteULike Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
J. McCormick, G. S. J. Whitley, P. Le Bouteiller, and J. E. Cartwright
Soluble HLA-G regulates motility and invasion of the trophoblast-derived cell line SGHPL-4
Hum. Reprod.,
June 1, 2009;
24(6):
1339 - 1345.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. C. Douglas, C. A. VandeVoort, P. Kumar, T.-C. Chang, and T. G. Golos
Trophoblast Stem Cells: Models for Investigating Trophectoderm Differentiation and Placental Development
Endocr. Rev.,
May 1, 2009;
30(3):
228 - 240.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. Moreau, L. Contu, F. Alba, S. Lai, R. Simoes, S. Orru, C. Carcassi, M. Roger, M. Rabreau, and E. D. Carosella
HLA-G Gene Polymorphism in Human Placentas: Possible Association of G*0106 Allele with Preeclampsia and Miscarriage
Biol Reprod,
September 1, 2008;
79(3):
459 - 467.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. D. Carosella, B. Favier, N. Rouas-Freiss, P. Moreau, and J. LeMaoult
Beyond the increasing complexity of the immunomodulatory HLA-G molecule
Blood,
May 15, 2008;
111(10):
4862 - 4870.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. Y. Tan, J. F.V. Ho, Y. S. Chong, A. Loganath, Y. H. Chan, J. Ravichandran, C. G. Lee, and S. S. Chong
Paternal contribution of HLA-G*0106 significantly increases risk for pre-eclampsia in multigravid pregnancies
Mol. Hum. Reprod.,
May 1, 2008;
14(5):
317 - 324.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. Szekeres-Bartho and J. Balasch
Progestagen therapy for recurrent miscarriage
Hum. Reprod. Update,
January 1, 2008;
14(1):
27 - 35.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. I. Bondarenko, D. W. Burleigh, M. Durning, E. E. Breburda, R. L. Grendell, and T. G. Golos
Passive Immunization against the MHC Class I Molecule Mamu-AG Disrupts Rhesus Placental Development and Endometrial Responses
J. Immunol.,
December 15, 2007;
179(12):
8042 - 8050.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Coupel, A. Moreau, M. Hamidou, V. Horejsi, J.-P. Soulillou, and B. Charreau
Expression and release of soluble HLA-E is an immunoregulatory feature of endothelial cell activation
Blood,
April 1, 2007;
109(7):
2806 - 2814.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J.-J. Helwig and P. Le Bouteiller
Physiological Smooth Muscle Cell Apoptosis Contributes to the Uterine Vascular Remodeling in Human Early Pregnancy
Circ. Res.,
March 30, 2007;
100(6):
754 - 756.
[Full Text]
[PDF]
|
 |
|
|
|